Literature DB >> 3592628

Characterization of conditions in which dipyridamole enhances methotrexate toxicity in L1210 cells.

F M Muggia, P Slowiaczek, M H Tattersall.   

Abstract

In vitro studies in exponentially growing L1210 cells utilizing DNA flow cytometry and cell proliferation measurements indicate enhancement of methotrexate effects by Dipyridamole provided: Methotrexate concentrations exceed those required to shut off maximally de novo pathways of purine and pyrimidine synthesis (i.e. 30 nM for 48 h), and Dipyridamole concentrations exceed 3 microM. In 10% fetal calf serum, this concentration inhibits tritiated thymidine uptake by about 80%. These data should prove helpful in the planning of clinical studies with dipyridamole or other inhibitors of nucleoside transport used to potentiate inhibitors of de novo pathways.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3592628

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate.

Authors:  R Goel; R Sanga; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial.

Authors:  C S Higano; R B Livingston
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport.

Authors:  J M Hughes; M H Tattersall
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.